The British “Nature” magazine website recently published two papers from Chinese researchers, verifying the efficacy and safety of a new hypoglycemic drug jointly developed by Chinese and American pharmaceutical companies as monotherapy and treatment with combined oral hypoglycemic agents. These are two phase III clinical studies targeting Chinese type 2 diabetics. Relevant results have shown that mast peptides are superior to placebo or duracopeptide in blood sugar control and weight loss, and can also improve many cardiovascular metabolism, liver, and kidney-related indicators. According to reports, Maxidol is a glucagon/glucagon-like peptide-1 dual receptor agonist jointly promoted by China's Cinda Biopharmaceuticals Group and Eli Lilly Pharmaceuticals of the United States. Qian Lei, chief R&D officer of Cinda Biopharmaceutical Group Integrated Pipeline, who participated in the relevant research, said that the above research results provided high-quality evidence-based medical evidence for overweight, obese, and diabetics, and also showed China's scientific research capabilities in related fields. Diabetes is closely related to obesity. Being overweight can increase insulin resistance and is one of the main factors leading to the occurrence, progression, and complications of type 2 diabetes. Related complications can affect blood vessels, eyes, kidneys, feet, etc.

The British “Nature” magazine website recently published two papers from Chinese researchers, verifying the efficacy and safety of a new hypoglycemic drug jointly developed by Chinese and American pharmaceutical companies as monotherapy and treatment with combined oral hypoglycemic agents. These are two phase III clinical studies targeting Chinese type 2 diabetics. Relevant results have shown that mast peptides are superior to placebo or duracopeptide in blood sugar control and weight loss, and can also improve many cardiovascular metabolism, liver, and kidney-related indicators. According to reports, Maxidol is a glucagon/glucagon-like peptide-1 dual receptor agonist jointly promoted by China's Cinda Biopharmaceuticals Group and Eli Lilly Pharmaceuticals of the United States. Qian Lei, chief R&D officer of Cinda Biopharmaceutical Group Integrated Pipeline, who participated in the relevant research, said that the above research results provided high-quality evidence-based medical evidence for overweight, obese, and diabetics, and also showed China's scientific research capabilities in related fields. Diabetes is closely related to obesity. Being overweight can increase insulin resistance and is one of the main factors leading to the occurrence, progression, and complications of type 2 diabetes. Related complications can affect blood vessels, eyes, kidneys, feet, etc.